UCSF COVID-19: Extended Immunophenotyping Studies

  • Funded by National Institutes of Health (NIH)
  • Total publications:2 publications

Grant number: 3U19AI077439-13S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $506,680
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    UNIVERSITY OF CALIFORNIA-SAN FRANCISCO
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

We propose to rapidly apply key assays of patient samples derived from IMPACC studies tounderstand the critical features that characterize hospitalized patients with COVID-19, a pandemicdisease characterized by immune exacerbations of lung injury. These proposed studies are a naturaland focused extension of the work we are performing in the parent U19 award adapted to the urgentmedical need to better understand the pathogenesis of severe, life-threatening COVID-19 disease.We propose 5 site-specific studies that are highly complementary to assays being performed by theIMPACC national immunophenotyping cores here at UCSF and elsewhere. These include studiesthat focus on both airway cells and blood immune cells (including neutrophils) and utilize a set ofinnovative methods that allow for a detailed understanding of the nature and activation states ofspecific cell types within the airway and the blood. These studies promise to yield new insightsrelevant for understanding COVID-19 immunopathogenesis and predicting disease outcome andresponse to therapy, and could lead to novel therapeutic targets for this devastating disease.

Publicationslinked via Europe PMC

Last Updated:40 minutes ago

View all publications at Europe PMC

Tracheal aspirate RNA sequencing identifies distinct immunological features of COVID-19 ARDS.

Global absence and targeting of protective immune states in severe COVID-19.